U.S. Markets closed

Spruce Point: Dexcom Could Fall 45-60%

Brett Hershman

DexCom, Inc. (NASDAQ: DXCM) shares are trading lower after a new report from Spruce Point Capital argued the stock could fall 45-60 percent.

The San Diego-based company manufacturers continuous glucose monitoring systems for diabetic patients.

Until now, the company’s G-Series model has been considered the gold standard, while its competitor Abbott Laboratories (NYSE: ABT) offered a cheaper, user-friendly alternative with the FreeStyle Libre, according to Spruce Point. 

Abbott is set to release the Libre 2 in the U.S. and Spruce Point said the launch will close most if not all technological gaps with Dexcom’s G-Series.

This move will put heavy pressure on Dexcom profits with little downside to Abbott's margin, the report said.

“The Street believes that the downmarket Libre is not a serious threat to Dexcom’s market, but the LIbre has taken [greater than 70 percent] incremental share of the U.S. Type 1 market and [greater than 95 percent] incremental share of the U.S. Type 2 market since first being released in the U.S." 

Dexcom has few avenues for near-term patient growth and will be effectively locked out of the Type 2 market until it releases a cheaper, downmarket CGM similar to the Libre, according to Spruce Point. 

“We see 45-60-percent near-term downside in DXCM shares after disappointing sales growth and a multiple re-rating, and even more potential future downside on long-term price pressure." 

DexCom shares were down 3.13 percent at $141.59 at the time of publication Thursday. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Photo courtesy of Dexcom. 

Latest Ratings for DXCM

Date Firm Action From To
Feb 2019 Morgan Stanley Maintains Equal-Weight Equal-Weight
Jan 2019 UBS Maintains Neutral Neutral
Jan 2019 Morgan Stanley Maintains Equal-Weight Equal-Weight

View More Analyst Ratings for DXCM
View the Latest Analyst Ratings

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.